Pradaxa safety profile confirmed in real-world data

21 March 2018

Pradaxa (dabigatran etexilate) has had its safety profile strengthened by new data from one of the largest real-world studies of its kind.

The data was revealed at the 2018 European Heart Rhythm Association conference in Barcelona, and will come as a boost to privately-owned German pharma manufacturer Boehringer Ingelheim, after the drug suffered to rival Eliquis (apixaban) in a different real-world study.

The GLORIA-AF studies tracked the outcomes of around 5,000 patients suffering from atrial fibrillation (AF) over two years, and reported low rates of stroke and major bleedingwhile on the drug (0.65% and 0.97% respectively).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK